The development of immunoconjugates for targeted cancer therapy

Nature Reviews Clinical Oncology

Volumn 11, Issue 11, 2014, Pages 637-648

  Smaglo, Brandon G ^a   Aldeghaither, Dalal ^a   Weiner, Louis M ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 414; ANTIBODY CONJUGATE; BRENTUXIMAB VEDOTIN; DNIB 0600A; GEMTUZUMAB OZOGAMICIN; GLEMBATUMUMAB VEDOTIN; IBRITUMOMAB TIUXETAN; INOTUZUMAB OZOGAMICIN; LORVOTUZUMAB MERTANSINE; MOXETUMOMAB PASUDOTOX; SAR 3419; TOSITUMOMAB I 131; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BREAST CANCER; CANCER THERAPY; DRUG APPROVAL; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; FOLLICULAR LYMPHOMA; GLIOBLASTOMA; HAIRY CELL LEUKEMIA; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MERKEL CELL TUMOR; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; REVIEW; SMALL CELL LUNG CANCER; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PASSIVE IMMUNIZATION; PROCEDURES; PROTEIN ENGINEERING; TRENDS;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOCONJUGATES; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN ENGINEERING;

EID: 84908551380     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2014.159     Document Type: Review

References (151)

1. Paul Ehrlich-Biographical. Nobelprize.org [online], http://www.nobelprize.org/ nobel-prizes/medicine/laureates/1908/ ehrlich-bio.html (2014).
2. Anderson, C. S., Quinones, R. & Olson, M. R. Determining efficacy and side effects from the concurrent use of chemotherapy and radiation therapy for the management of adult solid tumors [abstract]. J. Clin. Oncol. 32 (Suppl.), e17640 (2014).
3. Van Cutsem, E. et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408-1417 (2009).
4. Fuchs, C. S. et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J. Clin. Oncol. 25, 4779-4786 (2007).
5. Hochster, H. S. et al. Safety and efficacy of oxaliplatin-fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): results of the TREE-Study. J. Clin. Oncol. 26, 3523-3529 (2008).
6. Reichert, J. M. et al. Monoclonal antibody successes in the clinic. Nat. Biotechnol. 23, 1073-1078 (2005).
7. Pro, B. et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J. Clin. Oncol. 30, 2190-2196 (2012).
8. Younes, A. et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J. Clin. Oncol. 30, 2183-2189 (2012).
9. Verma, S. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367, 1783-1791 (2012).
10. Sievers, E. L. & Senter, P. D. Antibody-drug conjugates in cancer therapy. Annu. Rev. Med. 64, 15-29 (2013).
11. Teicher, B. A. & Chari, R. V. J. Antibody conjugate therapeutics: challenges and potential. Clin. Cancer Res. 17, 6389-6397 (2011).
12. Thurber, G. M., Schmidt, M. M. & Wittrup, K. D. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv. Drug Deliv. Rev. 60, 1421-1434 (2008).
13. Chari, R. V. J. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc. Chem. Res. 41, 98-107 (2008).
14. Kapoor, P. et al. Anti-CD20 monoclonal antibody therapy in multiple myeloma. Br. J. Haematol. 141, 135-148 (2008).
15. Yarden, Y. The EGFR family and its ligands in human cancer: signaling mechanisms and therapeutic opportunities. Eur. J. Cancer 37, S3-S8 (2001).
16. Colcher, D. et al. Pharmacokinetics and biodistribution of genetically-engineered antibodies. Q. J. Nucl. Med. 42, 225-241 (1998).
17. Wells, A. EGF receptor. Int. J. Biochem. Cell Biol. 31, 637-643 (1999).
18. Colby, D. W. et al. Development of a human light chain variable domain (V(L)) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display. J. Mol. Biol. 342, 901-912 (2004).
19. Binz, H. K. Amstutz, P. & Pluckthun, A. Engineering novel binding proteins from nonimmunoglobulin domains. Nat. Biotechnol. 23, 1257-1268 (2005).
20. Cao, Y. et al. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity. Mol. Cancer Ther. 11, 143-153 (2012).
21. Ducancel, F. & Muller, B. H. Molecular engineering of antibodies for therapeutic and diagnostic purposes. mAbs 4, 445-457 (2012).
22. Weiner, L. M. et al. I. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16. Cancer Res. 53, 94-110 (1993).
23. Yokota, T. et al. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms. Cancer Res. 53, 3776-3783 (1993).
24. Adams, G. P. et al. Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 anti-c-erbB-2 single-chain Fv: effects of dose escalation and repeated i.v. administration. Cancer Immunol. Immunother. 40, 299-306 (1995).
25. Adams, G. P. et al. Enhanced tumor specificity of 741F8-1 (sFv')2, an anti-c-erbB-2 single-chain Fv dimer, mediated by stable radioiodine conjugation. J. Nucl. Med. 36, 2276-2281 (1995).
26. Saga, T. et al. Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. Proc. Natl Acad. Sci. USA 92, 8999-9003 (1995).
27. Adams, G. P. et al. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res. 58, 485-490 (1998).
28. Zhang, Y. & Pastan, I. High shed antigen levels within tumours: an additional barrier to immunoconjugate therapy. Clin. Cancer Res. 14, 7981-7986 (2008).
29. Adams, G. P. et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 61, 4750-4755 (2001).
30. Ackerman, M. E., Pawlowski, D. & Wittrup, K. D. Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids. Mol. Cancer Ther. 7, 2233-2240 (2008).
31. Mayer, A. et al. Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain Fv antibody. Clin. Cancer Res. 5, 1711-1719 (2000).
32. Singh, R., Zhang, Y., Pastan, I. & Kreitman, R. J. Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy. Clin. Cancer Res. 18, 152-160 (2012).
33. Pasquetto, M. V., Vecchia, L., Covini, D., Digilio, R. & Scotti, C. Targeted drug delivery using immunoconjugates: principles and applications. J. Immunother. 34, 611-628 (2011).
34. Marks, J. D. et al. Human antibody fragments specific for human blood group antigens from a phage display library. Biotechnology 11, 1145-1149 (1993).
35. Winter, G., Griffiths, A. D., Hawkins, R. E. & Hoogenboom, H. R. Making antibodies by phage display technology. Annu. Rev. Immunol. 12, 433-455 (1994).
36. Griffiths, A. D. & Duncan, A. R. Strategies for selection of antibodies by phage display. Curr. Opin. Biotechnol. 1, 102-108 (1998).
37. Feldhaus, M. J. & Siegel, R. W. Yeast display of antibody fragments: a discovery and characterization platform. J. Immunol. Methods 290, 69-80 (2004).
38. Graff, C. P., Chester, K., Begent, R. & Wittrop, K. D. Directed evolution of an anti-carcinoembrynoic antigen sc Fv with a 4-day monovalent dissociation half-time at 37°C. Protein Eng. Des. Sel. 17, 293-304 (2004).
39. Dubreuil, O. et al. Fine tuning of specificity of an anti-progesterone antibody by first and second sphere residue engineering. J. Biol. Chem. 280, 24880-24887 (2005).
40. Clark, L. A. et al. Affinity enhancement of an in vivo matured therapeutic antibody using structure-based computational design. Protein Sci. 15, 949-960 (2006).
41. Lippow, S. M., Wittrup, K. D. & Tidor, B. Computational design of antibody-affinity improvement beyond in vivo maturation. Nat. Biotechnol. 25, 1171-1176 (2007).
42. Ward, E. S., Zhou, J., Ghetie, V. & Ober, R. J. Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans. Int. Immunol. 15, 187-195 (2003).
43. 2, and Fab' in mice. Cancer Res. 46, 3969-3978 (1986).
44. Adams, G. P. et al. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br. J. Cancer 77, 1405-1412 (1998).
45. Wu, A. M. Engineered antibodies for molecular imaging of cancer. Methods 65, 139-147 (2014).
46. Olafsen, T., Sirk, S. J., Olma, S., Shen, C. K. & Wu, A. M. ImmunoPET using engineered antibody fragments: fluorine-18 labeled diabodies for same-day imaging. Tumour Biol. 33, 669-677 (2012).
47. Sanderson, R. J. In vivo drug-linker stability of an anti-CD30 dipeptide-liked auristatin immunoconjugate. Clin. Cancer Res. 11, 843-852 (2005).
48. Ducry, L. & Stump, B. Antibody-drug congjugates: linking cytotoxic payloads to monoclonal antibodies Bioconjug. Chem. 21, 5-13 (2010).
49. Junutula, J. R. et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol. 26, 925-932 (2008).
50. Koblinski, J. E., Ahran, M. & Sloane, B. F. Unraveling the role of proteases in cancer. Clin. Chim. Acta 291, 113-135 (2000).
51. Sjogren, H. O. et al. Human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetant rates. Cancer Res. 57, 4530-4536 (1997).
52. Saleh, M. N. et al. Phase I trial of the anti-lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J. Clin. Oncol. 18, 2282-2292 (2000).
53. 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment in patients with colorectal cancer. Clin. Cancer Res. 10, 5014-5021 (2004).
54. Kreitman, R. J. et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox in patients with hairy cell leukemia. J. Clin. Oncol. 30, 1822-1828 (2012).
55. Hassan, R. et al. Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci. Transl. Med. 5, 208ra147 (2013).
56. Dosio, F., Brusa, P. & Cattel, L. Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components. Toxins 3, 848-883 (2011).
57. Sutherland, M. S. et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J. Biol. Chem. 281, 10540-10547 (2006).
58. US Department of Health and Human Services. Brentuximab vedotin information. US Food and Drug Administration [online], http://www.fda.gov/ Drugs/DrugSafety/PostmarketDrugSafety InformationforPatientsandProviders/ ucm287672.htm (2012).
59. Ujjani, C. & Cheson B. D. The current status and future impact of targeted therapies in non-Hodgkin lymphoma. Expert Rev. Hematol. 6, 191-203 (2013).
60. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/ NCT01851200?term=antibody+drug+ conjugate+solid+tumors&rank=6 ( 2014).
61. Ansell, S. M. et al. Phase I/II study of an anti-CD30 monoclonal antibody in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J. Clin. Oncol. 25, 2764-2769 (2007).
62. LoRusso, P. M., Weiss, D., Guardino, E., Grish, S. & Sliwkowski, M. X. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin. Cancer Res. 17, 6437-6447 (2011).
63. Lewis Phillips, G. D. et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 68, 9280-9290 (2008).
64. Barok, M., Tanner, M., Koninki, K. & Isola, J. Trasuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res. 13, R46 (2011).
65. Burris, H. A. et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J. Clin. Oncol. 29, 398-405 (2011).
66. Krop, I. E. et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trasuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 30, 3234-3241 (2012).
67. US Department of Health and Human Services. Ado-trastuzumab emtansine. US Food and Drug Administration [online], http:// www.fda.gov/Drugs/InformationOnDrugs/ ApprovedDrugs/ucm340913.htm (2013).
68. Bross, P. F. et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 7, 1490-1496 (2001).
69. Ricart, A. D. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin. Cancer Res. 17, 6417-6427 (2011).
70. Petersdorf, S. et al. Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia [abstract]. Blood 114, a790 (2009).
71. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/ NCT01564784?term=inotuzumab+ozogamicin& recr=Open&rank=5 ( 2014).
72. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/ NCT01535989?term=inotuzumab+ozogamicin& recr=Open&rank=3 ( 2014).
73. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/ NCT01562990?term=inotuzumab+ozogamicin& recr=Open&rank=4 ( 2014).
74. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/ NCT01664910?term=inotuzumab+ozogamicin& recr=Open&rank=1 ( 2014).
75. Ribrag, V. et al. A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin. Cancer Res. 20, 213-220 (2014).
76. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/ NCT01440179?term=SAR3419&rank=3 ( 2014).
77. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/ NCT01472887?term=SAR3419&rank=1 ( 2014).
78. Maric, G., Rose, A. A., Annis, M. G. & Siegel, P. M. Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer. Onco. Targets Ther. 6, 839-852 (2013).
79. Celdex Therapeutics. Final Data from Celldex Therapeutic's CDX-011 phase 2 study in metastatic breast cancer supports overall survival benefit in patients with high GPNMB expression [online], http://ir.celldex.com/ releasedetail.cfm?ReleaseID=725688 (2012).
80. Naumovski, L. & Junutula, J. R. Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer. Curr. Opin. Mol. Ther. 12, 248-257 (2010).
81. Hamid, O. et al. Frequent dosing and GPNMB expression with CDX-011, an antibody-drug conjugate, in patients with advanced melanoma. J. Clin. Oncol. 28, 15s (2010).
82. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/ NCT01997333?term=glembatumumab&rank=1 ( 2014).
83. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/ NCT00346385?term=antibody+drug+ conjugate+solid+tumors&rank=11 ( 2014).
84. Woll, P. Abstract B237: Clinical experience of MGN901 (BB-10901, huN901-DM1) in patients with Merkel cell carcinoma (MCC). Mol. Cancer Ther. 8, B237 (2009).
85. Gan, H. K. et al. A phase I study evaluating ABT-414 in combination with temozolamide for subjects with recurrent or unresectable glioblastoma. J. Clin. Oncol. 32, 5s (2014).
86. Burris, H. A. et al. A phase I study of DNIB0600A, an antibody-drug conjugate targeting NaPi2b, in patients with non-small cell lung cancer or platinum-resistant ovarian cancer. J. Clin. Oncol. 32, 5s (2014).
87. Marx, J. L. in A Revolulation in Biotechnology (ed. Marx, J. L.) 145-158 (The Press Syndicate of the University of Cambridge, 1989).
88. Witzig, T. E. et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J. Clin. Oncol. 20, 3262-3269 (2002).
89. US Department of Health and Human Services. britumomab tiuxetan product approval nformation. US Food and Drug Administration [online], http://www. fda.gov/Drugs/ DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/ ApprovalApplications/Therapeutic BiologicApplications/ucm093379.htm ( 2009).
90. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/ NCT01434472?term=Ibritumomab+tiuxetan& recr=Open&rank=3 ( 2014).
91. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/ NCT01686165?term=Ibritumomab+Tiuxetan& recr=Open&rank=7 ( 2014).
92. Kaminski, M. S. et al. Pivotal study of iodine 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J. Clin. Oncol. 19, 3918-3928 (2001).
93. Timmerman, L. Why good drugs sometimes fail: the Bexxar story. Xconomy [online], http:// www.xconomy.com/national/2013/08/26/ why-good-drugs-sometimes-fail-in-the-market-the-bexxar-story/ (2013).
94. Steiner, M. & Neri, D. Antibody-radionucleotide conjugates for cancer therapy: historical considerations and new trends. Clin. Cancer Res. 17, 6406-6416 (2011).
95. Song, H. & Sgouros, G. Radioimmunotherapy of solid tumors: searching for the right target. Current Drug Deliv. 8, 26-44 (2011).
96. Sharkey, R. M., Karacay, H., Govindan, S. V. & Goldenberg, D. M. Combination radioimmunotherapy and chemoimmunotherapy nvolving different or the same targets improves therapy of human pancreatic carcinoma xenograft models. Mol. Cancer Ther. 10, 1072-1081 (2011).
97. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01956812?term=Clivatuzumab&rank=1 ( 2014).
98. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/ NCT01125085?term=radioimmunotherapy+ solid&rank=1 ( 2014).
99. Press, O. W. et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD-20 expressing lymphoma xenografts. Blood 98, 2535-2543 (2001).
100. Knox, S. J. et al. Phase II trial of Yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/ streptavidin in patients with metastatic colorectal cancer. Clin. Cancer Res. 6, 406-414 (2000).
101. Park, S. I. et al. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. Blood 116, 4231-4239 (2010).
102. Baidoo, K. E., Yong, K. & Brechbiel, M. W. Molecular pathoways: targeted α-particle radiation therapy. Clin. Cancer Res. 19, 530-537 (2013).
103. Kim, Y. S. & Brechbiel, M. W. An overview of targeted alpha therapy. Tumour Biol. 33, 573-590 (2012).
104. Gould, B. J. et al. Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies. J. Natl Cancer Inst. 81, 775-781 (1989).
105. Weiner, L. M. et al. Phase I evaluation of an anti-breast cancer monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate. Cancer Res. 49, 4062-4067, (1989).
106. Fitzgerald, D. J., Wayne, A. S., Kreitman, R. J. & Pastan, I. Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res. 71, 6300-6309 (2011).
107. Chaudhary, V. K. et al. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature 339, 394-397 (1989).
108. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/ NCT01829711?term=moxetumomab+ pasudotox&rank=1 ( 2014).
109. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/ NCT01891981?term=moxetumomab+ pasudotox&rank=2 ( 2014).
110. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/ NCT00659425?term=moxetumomab+ pasudotox&rank=4 ( 2014).
111. Bogner, C. et al. Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression. Br. J. Haematol. 148, 99-109 (2009).
112. Traini, R. et al. ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of Pseudomonas exotoxin-based proteins to the cell cytosol. Mol. Cancer Ther. 9, 2007-2015 (2010).
113. Amundson, S. A. et al. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res. 60, 6101-6110 (2000).
114. Mattoo, A. R., Pastan, I. & Fitzgerald, D. Combination treatmens with the PKC inhibitor, enzastaurin, enhance the cytotoxicity of the anti-mesothelin immunotoxin, SS1P. PLoS ONE 8, e75576 (2013).
115. Liu, W. et al. Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proc. Natl Acad. Sci. USA 109, 11782-11787 (2012).
116. Onda, M. et al. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc. Natl Acad. Sci. USA 105, 11311-11316 (2008).
117. Pai, L. H. et al. Inhibition of antibody response to Pseudomonas exotoxin by 15-deoxyspergualin in mice. Cancer Res. 50, 7750-7753 (1990).
118. Gelber, E. E. et al. Effect of immunosuppressive agents on the immunogenicity and efficacy of an immunotoxin in mice. Clin. Cancer Res. 4, 1297-1304 (1998).
119. Hassan, R., Williams-Gould, J., Watson, T., Pai-Scherf, L. & Pastan, I. Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1. Clin. Cancer Res. 10, 16-18 (2004).
120. Mazor, R. et al. Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A. Proc. Natl Acad. Sci. USA 109, E3597-E3603 (2012).
121. Basu, A. et al. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Bioconjugate Chem. 17, 618-630 (2006).
122. Kreitman, R. J. Immunotoxins for targeted cancer therapy. AAPS J. 8, E532-E551 (2006)
123. Becerril, B., Poul, M. A. & Marks, J. D. Towards selection of internalizing antibodies from phage libraries. Biochem. Biophys. Res. Commun. 255, 386-393 (1999).
124. Nielsen, U. B. et al. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by phage antibody selected for cellular endocytosis. Biochim. Biophys. Acta 1591, 109-118 (2002).
125. Noble, C. O. et al. Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. Cancer Chemother. Pharmacol. 64, 741-751 (2009).
126. El-Bayoumi, T. A. & Tochilin, V. P. Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin. Cancer Res. 15, 1973-1980 (2009).
127. Xu, L. et al. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol. Cancer Ther. 5, 337-346 (2002).
128. Mamot, C. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. Lancet Oncol. 13, 1234-1241 (2012).
129. Senzer, N. et al. Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol. Ther. 21, 1096-1103 (2013).
130. Kelly, E. J., Hadac, E. M., Greiner, S. & Russell, S. J. Engineering microRNA responsiveness to decrease virus pathogenicity. Nat. Med. 14, 1278-1283 (2008).
131. Galanis, E. et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res. 70, 875-882 (2010).
132. Liu, X. et al. Enhanced pancreatic cancer gene therapy by combination of adenoviral vector expressing c-erb-B2-targeted immunotoxin with a replication-competent adenovirus or etoposide. Hum. Gene Ther. 21, 157-170 (2010).
133. Sharkey, R. M. & Goldenberg, D. M. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J. Clin. 56, 226-243 (2006).
134. Fournier, P. & Schirrmacher, V. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer. BioDrugs, 27, 35-53 (2013).
135. List, T. & Neri, D. Immunocytokines: a review of molecules in clinical development for cancer therapy. Clin. Pharmacol. 5, 29-45 (2013).
136. Pasche, N. & Neri, D. Immunocytokines: a novel class of potent armed antibodies. Drug Discov. Today 17, 583-590 (2012).
137. Carnemolla, B. et al. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 99, 1659-1665 (2002).
138. Borsi, L. et al. Selective targeted delivery of TNF-alpha to tumor blood vessels. Blood 102, 4384-4392 (2003).
139. Halin, C. et al. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat. Biotechnol. 20, 264-269 (2002).
140. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/ NCT01134250?term=F16-IL2&rank=1 ( 2014).
141. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/ NCT02054884?term=F16-IL2&rank=2 ( 2014).
142. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/ NCT02076646?term=L19-IL2&recr=Open& rank=1 ( 2014).
143. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/ NCT02076633?term=L19-IL2&recr=Open& rank=2 ( 2014).
144. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/ NCT01417546?term=NHS-IL12&rank=1 ( 2014).
145. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/ NCT02076620?term=L19-TNF&recr=Open& rank=1 ( 2014).
146. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/ NCT02076633?term=L19-IL2&recr=Open& rank=2 ( 2014).
147. Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A. & Kinzler, K. W. Cancer genome landscapes. Science 339, 1546-1558 (2013).
148. Robinson, M. K. et al. Quantitative immune-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res. 65, 1471-1478 (2005).
149. Rudnick, S. I. et al. Influsence of affinity and antigen internalization on the uptake and penetration of anti-HER2 antibodies in solid tumors. Cancer Res. 71, 2250-2259 (2011).
150. Schlom, J. Therapeutic cancer vaccines: current status and moving forward. J. Natl Cancer Inst. 104, 599-613 (2012).
151. Disis, M. L. et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J. Clin. Oncol. 27, 4685-4692 (2009).